Agersø, Henrik

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 510

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 444

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 279

Pharmacokinetics of the Rapid-Acting Insulin Analog, Insulin Aspart, in Rats, Dogs, and Pigs, and Pharmacodynamics of Insulin Aspart in Pigs

Plum, A., Agersø, H., & Andersen, L. (2000) · Drug Metabolism and Disposition

Diabetes Management and ResearchVeterinary Pharmacology and Anesthesia

Cited by 56

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach

Papathanasiou, T., Strathe, A., Agersø, H., Lund, T. M., & Overgaard, R. V. (2020) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 18